Amsterdam, Netherlands

Marco Guadagnoli

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Marco Guadagnoli: Innovator in Antibody Research

Introduction

Marco Guadagnoli is a prominent inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 2 patents, Guadagnoli's work focuses on innovative solutions for inflammatory diseases and cancer.

Latest Patents

Guadagnoli's latest patents include groundbreaking inventions related to antibodies against a proliferating inducing ligand (APRIL). The first patent details a binding compound that specifically targets human APRIL. This invention provides compositions of anti-APRIL specific antibodies and outlines methods for using these antibodies to modulate the biological activity of APRIL. This is particularly relevant in the context of inflammatory diseases, inhibition of cell proliferation, and cancer treatment.

Career Highlights

Marco Guadagnoli is associated with Bionovion Holding B.V., where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from serious health conditions.

Collaborations

Guadagnoli collaborates with esteemed colleagues in the field, including Jan Paul Medema and Hans Van Eenennaam. These partnerships enhance the scope and impact of his research endeavors.

Conclusion

Marco Guadagnoli stands out as an innovative inventor in the biotechnology sector, with a focus on antibody development for critical health issues. His contributions are paving the way for new therapeutic strategies in the fight against diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…